These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 11719669

  • 21. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents.
    Thomeer MG, Willemssen FE, Biermann KK, El Addouli H, de Man RA, Ijzermans JN, Dwarkasing RS.
    J Magn Reson Imaging; 2014 May; 39(5):1259-64. PubMed ID: 23897798
    [Abstract] [Full Text] [Related]

  • 22. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT, Marin D, Boll DT, Husarik DB, Davis DE, Feuerlein S, Merkle EM.
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [Abstract] [Full Text] [Related]

  • 23. Telangiectatic focal nodular hyperplasia: US, CT, and MR imaging findings with histopathologic correlation in 13 cases.
    Attal P, Vilgrain V, Brancatelli G, Paradis V, Terris B, Belghiti J, Taouli B, Menu Y.
    Radiology; 2003 Aug; 228(2):465-72. PubMed ID: 12819340
    [Abstract] [Full Text] [Related]

  • 24. Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.
    Grazioli L, Morana G, Caudana R, Benetti A, Portolani N, Talamini G, Colombari R, Pirovano G, Kirchin MA, Spinazzi A.
    Invest Radiol; 2000 Jan; 35(1):25-34. PubMed ID: 10639033
    [Abstract] [Full Text] [Related]

  • 25. Focal nodular hyperplasia of the liver: MR findings in 35 proved cases.
    Lee MJ, Saini S, Hamm B, Taupitz M, Hahn PF, Seneterre E, Ferrucci JT.
    AJR Am J Roentgenol; 1991 Feb; 156(2):317-20. PubMed ID: 1898806
    [Abstract] [Full Text] [Related]

  • 26. Histopathologically confirmed focal nodular hyperplasia of the liver: gadoxetic acid-enhanced MRI characteristics.
    Grieser C, Steffen IG, Seehofer D, Kramme IB, Uktolseya R, Scheurig-Muenkler C, Hamm B, Denecke T.
    Magn Reson Imaging; 2013 Jun; 31(5):755-60. PubMed ID: 23219272
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions.
    Pirovano G, Vanzulli A, Marti-Bonmati L, Grazioli L, Manfredi R, Greco A, Holzknecht N, Daldrup-Link HE, Rummeny E, Hamm B, Arneson V, Imperatori L, Kirchin MA, Spinazzi A.
    AJR Am J Roentgenol; 2000 Oct; 175(4):1111-20. PubMed ID: 11000175
    [Abstract] [Full Text] [Related]

  • 28. Focal nodular hyperplasia: findings at state-of-the-art MR imaging, US, CT, and pathologic analysis.
    Hussain SM, Terkivatan T, Zondervan PE, Lanjouw E, de Rave S, Ijzermans JN, de Man RA.
    Radiographics; 2004 Oct; 24(1):3-17; discussion 18-9. PubMed ID: 14730031
    [Abstract] [Full Text] [Related]

  • 29. Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients.
    Vilgrain V, Fléjou JF, Arrivé L, Belghiti J, Najmark D, Menu Y, Zins M, Vullierme MP, Nahum H.
    Radiology; 1992 Sep; 184(3):699-703. PubMed ID: 1509052
    [Abstract] [Full Text] [Related]

  • 30. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia.
    Vanhooymissen IJSML, Thomeer MG, Braun LMM, Gest B, van Koeverden S, Willemssen FE, Hunink M, De Man RA, Ijzermans JN, Dwarkasing RS.
    J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977
    [Abstract] [Full Text] [Related]

  • 31. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S, Gupta RT, Boll DT, Merkle EM.
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [Abstract] [Full Text] [Related]

  • 32. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial.
    Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO.
    Invest Radiol; 2008 Jul; 43(7):504-11. PubMed ID: 18580333
    [Abstract] [Full Text] [Related]

  • 33. Detection of liver metastases: comparison of gadobenate dimeglumine-enhanced and ferumoxides-enhanced MR imaging examinations.
    del Frate C, Bazzocchi M, Mortele KJ, Zuiani C, Londero V, Como G, Zanardi R, Ros PR.
    Radiology; 2002 Dec; 225(3):766-72. PubMed ID: 12461259
    [Abstract] [Full Text] [Related]

  • 34. Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.
    Ba-Ssalamah A, Schima W, Schmook MT, Linnau KF, Schibany N, Helbich T, Reimer P, Laengle F, Wrba F, Kurtaran A, Ryan M, Mann FA.
    AJR Am J Roentgenol; 2002 Dec; 179(6):1447-56. PubMed ID: 12438034
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Half-dose gadobenate dimeglumine versus standard-dose gadodiamide in dynamic magnetic resonance imaging of non-cirrhotic livers: a retrospective intra-individual crossover comparison.
    Homayoon B, Diwakar H, Strovski E, Bakshi D, Harris AC, Thoeni RF, Chang SD.
    Abdom Imaging; 2014 Oct; 39(5):955-62. PubMed ID: 24676875
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.